The purpose of the study is to evaluate the safety and effectiveness of Cinryze in managing the acute phase of subarachnoid hemorrhage. Participants in the study will receive either Cinryze or a placebo through an IV infusion, which means the treatment is given directly into a vein. The study will monitor participants for any complications during their hospital stay and assess their neurological condition over a period of 14 days. Researchers will also look at the activity of the complement system in the blood and spinal fluid, as well as other factors like the length of stay in the intensive care unit and the number of days on a ventilator.

By temporarily blocking the complement system, the study aims to limit the risk of delayed cerebral ischemia, a condition where the brain does not get enough blood flow, which can occur after a subarachnoid hemorrhage. The hope is that this approach will lead to better recovery and outcomes for patients by reducing the body’s inflammatory response. The trial is expected to start recruiting participants in November 2024 and aims to complete by August 2025.

The purpose of the study is to see whether the active drug can lower the risk of brain ischemia and related clot‑related problems after the bleed. Over a period of 14 days, participants are monitored for signs of blood clots that could block vessels (thromboembolic events) and for any neurological worsening. Doctors use a brain scan called MRI and a scoring system known as NIHSS to check for new areas of damage, and they also watch for a condition called delayed cerebral ischemia, which is a later reduction in blood flow that can happen after the initial bleed. After the treatment period, follow‑up visits and scans are done to assess recovery.

The treatment being tested involves two main substances. The first is lidocaine hydrochloride, a local anesthetic that helps numb the area to reduce pain. The second is sodium chloride, commonly known as salt, which is used as a solvent to help deliver the lidocaine. Both substances are administered through a subcutaneous injection, which means they are injected just under the skin.

The purpose of the study is to determine how effective this nerve block treatment is in managing headache pain related to spontaneous subarachnoid hemorrhage. Participants in the study will receive the treatment and their headache pain will be monitored to see if there is a significant reduction in pain levels. The study will help understand if this approach can provide relief for those suffering from this type of headache.

The study will compare two groups of patients – one receiving cilostazol tablets (100 mg taken twice daily) along with nimodipine, and another receiving a placebo with nimodipine. The treatment will continue for 14 days while patients are in the hospital. Both the patients and their doctors will not know which treatment group they are in during the study.

The research aims to determine if adding cilostazol to standard treatment helps improve patients’ ability to perform daily activities and live independently after six months. During the study, doctors will monitor patients for possible side effects, which may include fast heartbeat, dizziness, nausea, stomach discomfort, or bleeding. They will also track the development of any brain-related complications using various imaging techniques like CT scan and MRI.

The purpose of the study is to determine how well parecoxib works in improving the outcomes of patients with spontaneous subarachnoid hemorrhage. Participants in the study will receive either parecoxib or a placebo, and their progress will be monitored over a period of time. The study will assess various health outcomes, including the patients’ recovery and any side effects they may experience. The study will also look at other factors such as the length of hospital stay and any complications that may arise.

Throughout the study, patients will be closely observed to ensure their safety and to gather information on how parecoxib affects their condition. The results will help determine if parecoxib can be a beneficial treatment option for people with spontaneous subarachnoid hemorrhage. The study is designed to provide valuable insights into the potential benefits and risks of using parecoxib in this specific medical condition.

Participants in the study will receive either Deferoxamine or a placebo. The study will monitor the presence of new ischemia, which is a condition where blood flow (and thus oxygen) is restricted or reduced in a part of the body, at two weeks and six months after treatment. Additionally, the study will assess various outcomes related to neurological and functional health, such as serum ferritin levels and scores on scales like the modified Rankin Scale (mRS), the Glasgow Outcome Scale-Extended (GOS-E), and the EQ-5D, which is a standardized measure of health status.

The trial will follow participants over a period of time to gather data on these outcomes, aiming to provide insights into the potential benefits of Deferoxamine for individuals who have suffered from an aneurysmal subarachnoid hemorrhage. This research could help improve understanding and treatment of this serious condition.

The purpose of the study is to demonstrate the effectiveness of urea in correcting persistent hyponatremia, even when other management strategies have been adequately applied. Participants in the study will receive either urea or a placebo, which is a substance with no active medication. The study will monitor changes in sodium levels before and after the treatment period, which lasts up to five days. The study will also look at how much sodium intake is needed to correct the sodium levels, the mechanism of action of urea, and any potential side effects.

Throughout the study, researchers will assess the impact of the treatment on the length of hospital stay and the neurological outcomes three months after starting the treatment. They will also evaluate how quickly the sodium levels are corrected and whether the correction persists 48 hours after stopping the treatment. This trial aims to provide valuable insights into the management of hyponatremia in patients with subarachnoid hemorrhage.

Participants in the study will receive either the sphenopalatine block or a placebo to assess the effectiveness of the block in reducing headache pain and morphine consumption. The study will also monitor any complications that may arise from the sphenopalatine block technique, such as soft palate anesthesia, nosebleeds, or temporary hearing loss. The trial will involve several medications, including morphine hydrochloride, lidocaine hydrochloride, nefopam hydrochloride, and paracetamol, which are used for pain management.

The study will take place over a period of time, with participants being monitored for their pain levels and overall satisfaction with pain management. The goal is to improve pain management strategies for patients with subarachnoid hemorrhage, potentially reducing the need for strong pain medications like morphine. The trial is expected to start recruiting participants in early 2025 and aims to conclude by mid-2029.

Participants in the study will receive either the treatment EDV2209 or a placebo. The study is designed to be randomised and double-blind, meaning neither the participants nor the researchers will know who is receiving the actual treatment or the placebo. The treatment will be administered through a method called intracerebroventricular use, which involves delivering the medication directly into the brain’s ventricles, the fluid-filled spaces within the brain.

The study will follow participants over a period to monitor their health and any side effects they may experience. Researchers will assess various health indicators, such as vital signs and laboratory results, to ensure the treatment is safe. Additionally, the study will evaluate the clinical outcomes of the participants using scales like the National Institute of Health Stroke Scale (NIHSS) and the Modified Rankin Scale (mRS) to measure recovery and progress. The study aims to provide valuable information about the potential benefits and risks of EDV2209 for patients with SAH.

Participants in the study will receive either a therapeutic or prophylactic dose of nadroparin calcium. The study will monitor various outcomes, including the rate of death within 30 days, as well as other potential complications such as delayed cerebral ischemia, which is a condition where the brain does not get enough blood, and venous thrombo-embolic complications, which involve blood clots. The study will also look at the occurrence of bleeding complications, the need for additional medical procedures, and the overall quality of life and cognitive functioning of the participants.

The study will continue for several months, with follow-up assessments to evaluate the participants’ health and recovery. These assessments will include checking for any new or ongoing health issues, such as hydrocephalus, which is a condition where fluid builds up in the brain, and the participants’ ability to return to their normal daily activities. The study will also use MRI scans to check for any changes in the brain, such as small areas of tissue damage, at six months after the initial treatment. The goal is to gather comprehensive data on the effectiveness and safety of nadroparin calcium in improving outcomes for patients with subarachnoid hemorrhage.

The purpose of the study is to evaluate how effective Milrinone, given through an intravenous infusion, is compared to a placebo in improving the neurological outcomes of patients three months after experiencing vasospasm following an aneurysmal subarachnoid hemorrhage. Participants in the study will receive either the Milrinone treatment or a placebo, and their progress will be monitored over a period of time to assess their recovery and overall health outcomes.

Throughout the study, various aspects of the participants’ health will be evaluated, including their recovery in terms of brain function and quality of life. The study will also look at the success of the treatment in terms of reducing the narrowing of blood vessels in the brain, as well as other health indicators such as the length of hospital stay and any changes in blood pressure or metabolism. The goal is to gather information that could help improve treatment strategies for patients with this serious condition.

Participants in the study will receive either milrinone or a placebo, in addition to their usual medical care, for a period of 10 days. The main goal is to assess the impact of milrinone on the size of any brain lesions, which are areas of damaged tissue, as seen on a CT scan one month after treatment. A CT scan, or computed tomography scan, is a type of imaging that helps doctors see inside the body. The study will also monitor other factors, such as the number of days spent in intensive care and any changes in brain function over time.

Throughout the study, researchers will collect information on various health outcomes, including the overall neurological health of participants at different time points, such as one month, three months, six months, and one year after treatment. This will help determine the long-term effects of milrinone on patients who have experienced a severe aneurysmal subarachnoid hemorrhage. The study is expected to continue until 2028, providing valuable insights into the potential benefits of milrinone for this serious condition.

Participants in the study will receive Levosimendan as a solution for infusion, which means it will be administered directly into the bloodstream through a drip. The study will also involve a comparison with a placebo to evaluate the effectiveness of the treatment. The main goal is to see if Levosimendan can reduce the risk of a complication called cerebral arterial vasospasm, which is a narrowing of the blood vessels in the brain that can occur after the initial bleeding.

The study will follow participants for a period of time to monitor the occurrence of vasospasms and other outcomes such as the rate of death, the impact on heart function, and recovery scores six months after treatment. This research is important to understand if Levosimendan can improve outcomes for patients with this serious condition.

The purpose of this study is to determine if this treatment can improve the recovery and safety of patients who have experienced aSAH. Participants in the study will receive either the treatment with Urokinase and Nimodipine or a placebo. The study will monitor patients over a period of time to assess their neurological recovery, which refers to how well their brain functions after the treatment. This will be evaluated by a healthcare professional using a scale that measures independence in daily activities.

Throughout the study, various aspects of the patients’ health will be observed, including their quality of life, mental health, and any potential side effects of the treatment. The study will also look at the occurrence of any further brain damage or complications. The goal is to gather information that could lead to better treatment options for individuals suffering from aSAH in the future.

The purpose of the study is to understand how dexamethasone affects recovery in patients with SAH, whether or not they initially show signs of inflammation in their blood. Participants in the study will receive either the dexamethasone treatment or a placebo. The study will monitor patients over a period of time to assess their recovery and any changes in their condition. This includes looking at survival rates, the length of time spent in the hospital, and any complications that may arise, such as delayed ischemic neurological deficits, which are problems with brain function that occur after the initial bleeding.

Throughout the study, various health indicators will be measured, such as levels of inflammation in the blood and overall quality of life. The study aims to provide valuable insights into whether dexamethasone can improve outcomes for patients who have suffered from an aneurysmal subarachnoid hemorrhage. The results will help determine if this treatment can be beneficial in managing the condition and improving patient recovery.